HEALTH DESKS / Oncology
Risk is not destiny. And a diet is not a cancer cure.
Cancer Risk Reduction. The WHO's cancer agency classifies processed meat as a Group 1 carcinogen; Ornish's trial studied lifestyle change in early prostate cancer.
The biological mechanism, unpacked.
IARC’s classification concerns the strength of evidence that an exposure can cause cancer, not a comparison of absolute risk with other Group 1 exposures. Ornish’s prostate trial examined PSA and other intermediate endpoints.
The limit of the evidence. PSA and cell-culture findings do not establish improved cancer survival. Never replace oncology care with a meal plan.
Bouvard V, Loomis D, Guyton KZ, et al. (IARC Monograph Working Group). The Lancet Oncology 16(16):1599–1600, 2015. PMID 26514947 · DOI
Inside the desk
A dietary pattern that did not reduce adenoma recurrence ↗
The Polyp Prevention Trial tested a combined dietary intervention, with a null recurrence result.
Soy after breast cancer: recurrence and mortality diverge ↗
A pooled survivor analysis extends the evidence beyond one cohort without turning observation into treatment.
Wheat bran and recurrent adenomas: the randomized null result ↗
A blinded high-versus-low supplement comparison did not establish protection.
Resistant starch in Lynch syndrome: read beyond colorectal cancer ↗
Long-term randomized follow-up found different results for colorectal and other Lynch-associated cancers.
Inside a chemotherapy trial, diet was still observational ↗
A stage III colon cancer analysis illustrates why the randomized label must stay with the assigned treatment.
Whole grains and colorectal cancer: reading the prospective evidence. ↗
A 2011 synthesis linked higher fiber and whole-grain intake with lower colorectal cancer incidence; it did not establish causation.
Soy and prostate cancer incidence: an association, not therapy. ↗
An updated observational meta-analysis separated soy foods, isoflavones and advanced disease rather than treating them as one outcome.
Soy foods in a survivor cohort: association, not therapy. ↗
Food observations and supplement claims need separate evidence.
Flaxseed research: the distance from a marker to a cure. ↗
A presurgical breast-cancer experiment measured tumor biology. It did not measure prevention or survival.
The chronological clinical registry
2000
Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group.
The Polyp Prevention Trial tested a combined dietary intervention, with a null recurrence result.
Schatzkin A, Lanza E, Corle D, Lance P et al.. The New England journal of medicine, 2000. PMID 10770979 · DOI
2000
Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.
A blinded high-versus-low supplement comparison did not establish protection.
Alberts DS, Martínez ME, Roe DJ, Guillén-Rodríguez JM et al.. The New England journal of medicine, 2000. PMID 10770980 · DOI
2005
Intensive lifestyle changes may affect the progression of prostate cancer
RCT in men with early, low-grade prostate cancer under active surveillance: PSA decreased in the vegan lifestyle group and rose in controls; patient serum inhibited LNCaP cancer cell growth more in the intervention group.
Ornish D, Weidner G, Fair WR, et al.. Journal of Urology 174(3):1065–1069, 2005. PMID 16094059 · DOI
2005
Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer
A small randomized presurgical trial in 32 patients compared a flaxseed muffin with a control muffin for roughly one month. Tumor proliferation and related biological markers changed in the flaxseed group. Biomarker signals are not proof of prevention, recurrence reduction or survival benefit; this study does not replace cancer treatment.
Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Clinical Cancer Research 11:3828–3835, 2005. PMID 15897583 · DOI
2007
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
A stage III colon cancer analysis illustrates why the randomized label must stay with the assigned treatment.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB et al.. JAMA, 2007. PMID 17699009 · DOI
2009
Soy food intake and breast cancer survival
A prospective Shanghai cohort of surgically treated breast-cancer survivors associated higher soy-food intake with lower mortality and recurrence. Highest versus lowest soy-protein quartile hazard ratios were 0.71 and 0.68. Self-reported diet and residual confounding limit causal interpretation; foods are not isolated isoflavone supplements or cancer treatment.
Shu XO, Zheng Y, Cai H, Gu K, et al.. JAMA, 2009. PMID 19996398 · DOI
2011
Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies.
A 2011 synthesis linked higher fiber and whole-grain intake with lower colorectal cancer incidence; it did not establish causation.
Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T.. BMJ (Clinical research ed.), 2011. PMID 22074852 · DOI
2012
Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women.
A pooled survivor analysis extends the evidence beyond one cohort without turning observation into treatment.
Nechuta SJ, Caan BJ, Chen WY, Lu W et al.. The American journal of clinical nutrition, 2012. PMID 22648714 · DOI
2015
Carcinogenicity of consumption of red and processed meat
The International Agency for Research on Cancer classified processed meat as carcinogenic to humans (Group 1) and red meat as probably carcinogenic (Group 2A), primarily based on colorectal cancer evidence.
Bouvard V, Loomis D, Guyton KZ, et al. (IARC Monograph Working Group). The Lancet Oncology 16(16):1599–1600, 2015. PMID 26514947 · DOI
2018
Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
An updated observational meta-analysis separated soy foods, isoflavones and advanced disease rather than treating them as one outcome.
Applegate CC, Rowles JL, Ranard KM, Jeon S, Erdman JW.. Nutrients, 2018. PMID 29300347 · DOI
2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.
Long-term randomized follow-up found different results for colorectal and other Lynch-associated cancers.
Mathers JC, Elliott F, Macrae F, Mecklin JP et al.. Cancer prevention research (Philadelphia, Pa.), 2022. PMID 35878732 · DOI
Registry entries are individual publications, not endorsements of a researcher’s entire body of work. Campbell and Greger are not listed as trial authors here without a verified, relevant publication.
Three days, on the plate.
An illustrative NANO meal pattern—not a clinical protocol, complete nutrition prescription or treatment. Portions, energy needs, allergies and medication must be individualized. These recipe concepts have not been clinically evaluated.
DAY 01
breakfast
Blueberry Walnut Morning OatsServe the stew with brown rice and steamed broccoli.
DAY 02
breakfast
Blueberry Walnut Morning OatsSwap barley for farro; use seasonal squash and a fresh lemon dressing.
DAY 03
breakfast
Blueberry Walnut Morning OatsUse different berries at breakfast; add steamed greens at dinner.